Skip to main content
. 2018 Feb 27;16(2):e05182. doi: 10.2903/j.efsa.2018.5182

Figure 61.

Figure 61

Trends in ampicillin (AMP), cefotaxime (CTX), ciprofloxacin (CIP), nalidixic acid (NAL) and tetracycline (TET) resistance in tested Salmonella spp. isolates from turkeys, EU MSs, 2008–2016

  • Statistical significance of trends over 4‐5 or more years was tested by a logistic regression model (p ≤ 0.05).
    Statistically significant increasing trends were observed for ampicillin in Spain, for ciprofloxacin and nalidixic acid in the Czech Republic, France, Hungary and Italy, for nalidixic acid in Austria, Spain and the United Kingdom, as well as for tetracycline in Hungary, Italy, Spain and the United Kingdom.
    Statistically significant decreasing trends were observed for ampicillin in the Czech Republic, Germany, Hungary, Italy, Poland and the United Kingdom, for ciprofloxacin in Austria, Spain and the United Kingdom, for cefotaxime in Hungary and Spain, for nalidixic acid in Germany and Poland, as well as for tetracycline in the Czech Republic and France.